<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962401</url>
  </required_header>
  <id_info>
    <org_study_id>RemodelWM3</org_study_id>
    <nct_id>NCT02962401</nct_id>
  </id_info>
  <brief_title>Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia</brief_title>
  <acronym>RemodelWM3</acronym>
  <official_title>An Open Label Non-randomized Phase II Study Exploring &quot;Chemo-free &quot; Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective national multicenter open label phase II Remodel WM3 trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label non-randomized Phase II Study exploring chemo-free treatment association with&#xD;
      Idelalisib and Obinutuzumab in Patient with relapsed refractory Waldenstrom's&#xD;
      Macroglobulinemia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>8 years</time_frame>
    <description>From date of registration until the date of first documented progression or date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rates (ORR)</measure>
    <time_frame>Month 8</time_frame>
    <description>treatment response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (RD)</measure>
    <time_frame>7 years and 4 months</time_frame>
    <description>from end of induction to the date of progression, relapse or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>through study completion, an average of 8 years</time_frame>
    <description>time from start of induction to stable disease, progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TTNT)</measure>
    <time_frame>through study completion, an average of 8 years</time_frame>
    <description>time from start of induction day 1 cycle 1 to time of the next treatment for progression or relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Idelalisib and Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of Idelalisib and Obinutuzumab&#xD;
Cycle 1 :&#xD;
Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. (2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15&#xD;
Cycle 2 - 6 :&#xD;
Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. day 1&#xD;
Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15&#xD;
Cycle 2 - 6 :&#xD;
Obinutuzumab 1000mg I.V.day 1</description>
    <arm_group_label>Idelalisib and Obinutuzumab</arm_group_label>
    <other_name>GA101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>6 cycles every 28 days&#xD;
Cycle 1 :&#xD;
Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment</description>
    <arm_group_label>Idelalisib and Obinutuzumab</arm_group_label>
    <other_name>Zydelig</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Confirmed CD20 positive WM, according to the recommendations of the 2nd Workshop on&#xD;
             WM.&#xD;
&#xD;
          -  Presence of at least one criterion for initiation of therapy, according to the 2nd&#xD;
             Workshop on WM.&#xD;
&#xD;
          -  Recurrent fever, night sweats, weight loss, fatigue&#xD;
&#xD;
          -  Hyperviscosity&#xD;
&#xD;
          -  Lympadenopathy which is either symptomatic or bulky more or equal to 5cm in maximum&#xD;
             diameter&#xD;
&#xD;
          -  Symptomatic hepatomegaly and/or splenomegaly&#xD;
&#xD;
          -  Symptomatic organomegaly and/or organ or tissue infiltration&#xD;
&#xD;
          -  Peripheral neuropathy due to WM&#xD;
&#xD;
          -  Symptomatic cryoglobulinemia&#xD;
&#xD;
          -  Cold agglutinin anemia&#xD;
&#xD;
          -  Immune hemolytic anemia and/or thrombocytopenia&#xD;
&#xD;
          -  Nephropathy related to WM&#xD;
&#xD;
          -  Amyloidosis related to WM&#xD;
&#xD;
          -  Hemoglobin less or equal than 10g dL&#xD;
&#xD;
          -  Platelet count less than 100 109 L&#xD;
&#xD;
          -  Prior treatment for WM comprising at least one regimen containing a therapeutic anti&#xD;
             CD20 monoclonal antibody rituximab administered for more or equal than 2 doses of&#xD;
             antibody treatment and or a therapeutic chemotherapy, alkylating agent, purine&#xD;
             analogue, bendamustine administered for more or equal than 2 cycles of treatment&#xD;
&#xD;
          -  Patients may be either relapsing progressing at least 6 months after the last&#xD;
             administration of first line or subsequent treatment or refractory progressing on or&#xD;
             within 6 months of first line or subsequent treatment&#xD;
&#xD;
          -  Number of prior regimens per lines 1 to 3&#xD;
&#xD;
          -  Life expectancy more than 3 months.&#xD;
&#xD;
          -  ECOG less or equal than 2.&#xD;
&#xD;
          -  Meet the following pretreatment laboratory criteria at the screening visit conducted&#xD;
             within 28 days of study enrollment:&#xD;
&#xD;
               -  ASAT 2.5 times the upper limit of institutional laboratory normal value.&#xD;
&#xD;
               -  ALAT 2.5 times the upper limit of institutional laboratory normal value.&#xD;
&#xD;
               -  Total bilirubin 1.5 times the upper limit of institutional laboratory normal&#xD;
                  value unless clearly related to the disease or Gilbert syndrome&#xD;
&#xD;
               -  Calculated or measured creatinin clearance by MDRD 40 mL minute.&#xD;
&#xD;
          -  Premenopausal fertile females must agree to use a highly effective method of birth&#xD;
             control for the duration of the therapy up to 6 months after end of therapy.&#xD;
&#xD;
          -  A highly effective method of birth control is defined as those which result in a low&#xD;
             failure rate when used consistently and correctly such as implants, injectables,&#xD;
             combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner.&#xD;
&#xD;
          -  Men must agree not to father a child for the duration of therapy and 6 months after&#xD;
             and must agree to advice a female partner to use a highly effective method of birth&#xD;
             control.&#xD;
&#xD;
          -  Voluntary written informed consent before carrying out any study related procedure not&#xD;
             part of normal medical care, with the understanding that consent may be withdrawn by&#xD;
             the subject at any time without prejudice to future medical care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with phosphatidylinositol 3 kinase PI3K inhibitors including&#xD;
             idelalisib or GA101&#xD;
&#xD;
          -  History of anaphylactic reaction following exposure to humanized monoclonal antibodies&#xD;
&#xD;
          -  Previous allogeneic transplantation&#xD;
&#xD;
          -  Treatment with any other investigational agent or participating in another trial&#xD;
             within 30 days prior to entering this study&#xD;
&#xD;
          -  History of other malignancy or chemotherapy radiotherapy for any neoplastic disease&#xD;
             other than WM prior to the study.&#xD;
&#xD;
               -  EXCEPTION: History of malignancy except basal cell carcinoma of the skin, in situ&#xD;
                  carcinoma of breast or cervix treated surgically with curative intent, or any&#xD;
                  malignancy that has been in CR for 5 years at minimum, or as deemed appropriate&#xD;
                  for inclusion in the trial as per approval by the investigator&#xD;
&#xD;
          -  Medical condition requiring the long-term estimated to be more than one month use of&#xD;
             oral corticosteroids.&#xD;
&#xD;
          -  Patients with signs of bacterial, viral or fungal infection&#xD;
&#xD;
          -  Preexisting hepatic enzyme elevation ASAT, ALAT&#xD;
&#xD;
          -  CMV PCR or antigenemia testing positive&#xD;
&#xD;
          -  Known history of drug induced liver injury, chronic active hepatitis C HCV, chronic&#xD;
             active hepatitis B HBV, alcoholic liver disease, non-alcoholic steatohepatitis,&#xD;
             primary biliary cirrhosis, on-going extra-hepatic obstruction caused by&#xD;
             cholelithiasis, cirrhosis of the liver or portal hypertension&#xD;
&#xD;
          -  HIV antibody positive&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb):&#xD;
             Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B&#xD;
             virus (HBV) DNA is undetectable (&lt; 20 IU). Patients with positive serology should be&#xD;
             referred to a hepatologist or gastroenterologist before start of treatment and should&#xD;
             be monitored and managed following local standards to prevent hepatitis reactivation.&#xD;
             Furthermore transaminases and HBV DNA quantification must be tested at weeks 4 and 8&#xD;
             after treatment start. Then transaminases must be tested at week 12 of treatment&#xD;
             start.&#xD;
&#xD;
          -  Preexisting pulmonary disease&#xD;
&#xD;
          -  Known history of drug induced pneumonitis&#xD;
&#xD;
          -  On-going inflammatory bowel disease&#xD;
&#xD;
          -  Women who are pregnant. Women who are breast-feeding and do not consent to discontinue&#xD;
             breast-feeding Women of childbearing age who are not willing to use effective&#xD;
             anti-conceptive methods for the duration of the study and 6 months after end of&#xD;
             therapy&#xD;
&#xD;
          -  Concurrent severe diseases which exclude the administration of therapy:&#xD;
&#xD;
          -  Heart insufficiency NYHA grade III IV, LVEF &lt; 50% and or RF &lt;30%, myocardial&#xD;
             infarction within the past 6 months prior to study&#xD;
&#xD;
          -  Severe chronic obstructive lung disease with hypoxemia&#xD;
&#xD;
          -  Severe diabetes mellitus&#xD;
&#xD;
          -  Hypertension difficult to control&#xD;
&#xD;
          -  Cerebral dysfunction&#xD;
&#xD;
          -  Richter's syndrome&#xD;
&#xD;
          -  Cardiac amyloidosis&#xD;
&#xD;
          -  Any of the following laboratory abnormalities, if not related to lymphoma:&#xD;
&#xD;
          -  Absolute neutrophils count &lt;1.5 x 109/L if not result of a bone marrow infiltration&#xD;
             Platelet count &lt;75 x 109/L if not result of a bone marrow infiltration.&#xD;
&#xD;
          -  Central Nervous System involvement by lymphoma&#xD;
&#xD;
          -  Vaccination with live vaccines within 28 days prior to study entry&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients listed on part&#xD;
             6.1 of GAZYVARO and ZYDELIG SmCP&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
          -  No consent for registration, storage and processing of the individual&#xD;
             disease-characteristics and course as well as information of the family physician&#xD;
             about study participation&#xD;
&#xD;
          -  Patient with mental deficiency preventing proper understanding of the requirements of&#xD;
             treatment&#xD;
&#xD;
          -  Person major under law control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine NOLLET, Mrs</last_name>
    <role>Study Director</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Project manager</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO internet site</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>E CRF</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

